Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Q1 2026 Earnings Presentation
34 slides from Revenio Group Oyj's earnings presentation, Apr 28, 2026
Slide 1: Q1/2026 Interim Report
Q1/2026 Interim Report April 28, 2026 1 28.4.2026 Revenio
Slide 2: Disclaimer
Q1/2026 INTERIM REPORT Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio Group Corporation’s shares. Group's past performance is no guide to future performance, and persons needing advice should consult an inde
Slide 3: Today's presenters
Q1/2026 INTERIM REPORT Today’s presenters Jouni Robin Erkki Toijala Pulkkinen Tala CEO CFO Vice President, Products 3 28.4.2026 Revenio
Slide 4: Agenda
Q1/2026 INTERIM REPORT Agenda 1. Business highlights 2. Financials for Q1/2026 3. Financial guidance for 2026 4. Joining forces with Visionix 5. Q&A 4 28.4.2026 Revenio
Slide 5: January-March highlights
Q1/2026 INTERIM REPORT January-March highlights Net sales EBIT • Reported net sales amounted to EUR 27.3 (26.1) million, an increase of 4.8% 27.3 2.4 • Currency-adjusted net sales increased by 8.4% MEUR (+4.8%) MEUR (-63.8%) • Operating profit was EUR 2.4 (6.6) million, or 8.8% of net sales, down by
Slide 6: Financials Q1/2026
Q1/2026 INTERIM REPORT Financials Q1/2026 6 28.4.2026 Revenio
Slide 7: Development of Revenio's key figures
Q1/2026 INTERIM REPORT Development of Revenio’s key figures MEUR 1-3/ 1-3/ Change 1-12/ 2026 2025 -% 2025 Net sales 27.3 26.1 4.8 109.7 • We incurred EUR 3.4 million of Gross margin 18.7 19.0 -1.3 77.8 one-time costs during the first 68.4 72.6 -5.8 70.9 Gross margin, % quarter EBITDA 3.5 7.7 -54.9 2
Slide 8: Very strong quarter in the US and EMEA
Q1/2026 INTERIM REPORT Very strong quarter in the US and EMEA Net sales (EUR million) • The currency-adjusted net 35 sales increased by 8.4% 31,2 30 29,1 30,5 • Sales during the review period 26,1 26,5 25,9 27,3 were generated from our 25,4 25 23,6 23,9 normal order flow, and unlike 23,2 22,3 22,0 i
Slide 9: Profitability affected by tariffs, FX changes and one-off costs
Q1/2026 INTERIM REPORT Profitability affected by tariffs, FX changes and one-off costs Adjusted operating profit EUR million and % (EBIT) • Operating profit was impacted 10 9,5 35 9,3 in particular by non-recurring 9 costs of approximately EUR 3.1 30 million related to the Visionix 8 7,2 acquisition
Slide 10: Balance sheet remains unlevered for now
Q1/2026 INTERIM REPORT Balance sheet remains unlevered for now • Equity ratio remains high Equity ratio and net gearing (%) • Major changes expected to the 90 4 equity ratio and net gearing 80,2 79,6 79,1 levels following the closing of 80 74,5 74,7 76,3 76,2 77,2 76,1 2 72,2 72,7 the Visionix trans
Slide 11: Cash flow from operations
Q1/2026 INTERIM REPORT Cash flow from operations Cash flow from operations (EUR million) 20 15,9 • Cash flow from operating 15 activities declined to EUR -3.4 (4.7) million. The decrease was primarily driven by increased 9,8 10 accounts receivable following 6,7 strong sales toward the end of 6,5 5,6
Slide 12: Shareholders on March 31, 2026
Q1/2026 INTERIM REPORT Shareholders on March 31, 2026* No. of shares % Verified Ownership 1. William Demant Invest A/S 6,532,461 24.48% 2026-03-31 2. SEB Funds 1,249,695 4.68% 2026-03-31 3. Vanguard 887,437 3.33% 2026-03-27 4. Ilmarinen Mutual Pension 803,118 3.01% 2026-03-27 Insurance Company 5. Da
Slide 13: Withdrawal of financial guidance for 2026
Q1/2026 INTERIM REPORT Withdrawal of financial guidance for 2026 Due to the transaction, Revenio has withdrawn its previous financial guidance and will provide updated financial guidance for 2026 after the completion of the transaction. Revenio’s previous financial guidance, published on February 11
Slide 14: Resolutions to be proposed to the General Meeting
Q1/2026 INTERIM REPORT Resolutions to be proposed to the General Meeting The completion of the transaction is subject to Revenio’s General Meeting resolving to: • Authorize the Board of Directors of Revenio to decide on a directed share issue of 2,485,797 new shares to the sellers in connection with
Slide 15: Joining forces with Visionix
Q1/2026 INTERIM REPORT Joining forces with Visionix 15 28.4.2026 Revenio
Slide 16: Revenio accelerates growth and value creation by joining forces with Visionix
Q1/2026 INTERIM REPORT Revenio accelerates growth and value creation by joining forces with Visionix Revenio joins forces with Visionix and becomes a leading turnkey solutions provider in the global eye care market. The rationale of the transaction is to bring together two highly complementary busin
Slide 17: Introduction to Visionix
Q1/2026 INTERIM REPORT Introduction to Visionix Company overview Key figures, 2025 • A French company founded in 1994 by Dr. Marc Abitbol Net sales Adjusted EBITDA Users • Specializes in innovative eye care devices supported by a cloud-based software platform € 143.4M € 16.6M 135,000 • Multinational
Slide 18: Strategic portfolio expansion
Q1/2026 INTERIM REPORT Strategic portfolio expansion 18 28.4.2026 Revenio
Slide 19: Creating a leading turnkey solutions provider in the global eye care market
Q1/2026 INTERIM REPORT Creating a leading turnkey solutions provider in the global eye care market $1 bn addressable market $2.5 bn addressable market Other Other 1.5 1.5 Fundus Fundus imaging 0.5 imaging 0.5 $4.0 bn $4.0 bn Global diagnostic Global diagnostic equipment market 0.2 Multi- 2.5x equipm
Slide 20: Product portfolio expansion in several customer segments
Q1/2026 INTERIM REPORT 1 2 3 Product portfolio expansion in several customer segments Optical retail Ophthalmology Optometry Substantial access to the optical retail segment is a key addition for Revenio Pharma research Home care Other healthcare & universities 20 28.4.2026 Revenio
Slide 21: Comprehensive product and software portfolio…
Q1/2026 INTERIM REPORT Comprehensive product and software portfolio… Tonometers Perimetry Fundus Multimodal OCT Refraction Edging & Software & imaging devices systems Mounting telehealth iCare ALTIUS iCare iCare iCare IC100 & iCare MAIA iCare EIDON family ILLUME HOME2 IC200 iCare RETCAD iCare iCare
Slide 22: …providing a turnkey solution for optical retail and optometry
Q1/2026 INTERIM REPORT ...providing a turnkey solution for optical retail and optometry Optometric customer journey Pre-test / Screening Refractive / Clinical examination Finishing & dispensing Connecting platform & clinical data management 22 28.4.2026 Revenio
Slide 23: Optical Retail and Clinical Optometry landscape is fast evolving
Q1/2026 INTERIM REPORT Optical Retail and Clinical Optometry landscape is fast evolving Italy • Example of the markets where optical retail is focusing on refractive examinations and spectacle sales & manufacturing • Ophthalmic diagnostics is centralized to ophthalmology • Large part of the markets
Slide 24: Expedited entry to the OCT segment - future-proofing the portfolio
Q1/2026 INTERIM REPORT 1 2 3 Expedited entry to the OCT segment - future-proofing the portfolio • Strategically compelling entry into the Optical Coherence Tomography (OCT) segment, where Revenio currently has no offering • The USD 0.7 billion OCT segment is among the fastest-growing segments in oph
Slide 25: OCT is at the center of ophthalmic diagnostics
Q1/2026 INTERIM REPORT 1 2 3 OCT is at the center of ophthalmic diagnostics OCT = Optical Coherence Tomography OCT Increasing prevalence of Growing interest among eye disease requiring clinicians for combining diagnostic accuracy and OCT and fundus imaging disease management OCT is becoming the Earl
Slide 26: Creating a leading turnkey solutions provider in the global eye care market
Q1/2026 INTERIM REPORT Creating a leading turnkey solutions provider in the global eye care market 2.5x increase in addressable market The widest customer segment coverage Expedited entry to the OCT segment - covering the entire diagnostic path - solutions for evolving market needs - broad use of th
Slide 27: Transaction financing and rights issue
Q1/2026 INTERIM REPORT Transaction financing and rights issue 27 28.4.2026 Revenio
Slide 28: Transaction terms and financing in brief
Q1/2026 INTERIM REPORT Transaction terms and financing in brief Revenio will acquire the entire share capital of LT International SAS, the parent company of Visionix International group Key transaction terms Transaction financing EUR 40 million Term loan facility Refinancing of EUR 130 million Net d
Slide 29: Post-completion rights issue
Q1/2026 INTERIM REPORT Post-completion rights issue Revenio plans to execute a EUR 80 million post-completion rights issue, subject to the decision of the General Meeting • Nordea has been engaged to act as the global coordinator and underwriter for the rights issue • Targeted to be arranged during
Slide 30: Summary
Q1/2026 INTERIM REPORT Summary 30 28.4.2026 Revenio
Slide 31: A phased value creation journey
Q1/2026 INTERIM REPORT A phased value creation journey 2026-2027 2028-2029 Beyond 2030 Quick wins & Mobilization Traction & Build-Up Continued growth & Sustained leadership • Combine organizations, processes and • Harvest full cross-sell synergies through • Extend market leadership through our syste
Slide 32: Thank you Robin!
Q1/2026 INTERIM REPORT Thank you Robin! 32 28.4.2026 Revenio
Slide 33: Q&A
Q1/2026 INTERIM REPORT Q&A 33 28.4.2026 Revenio
Slide 34: REVENIO
REVENIO